|
1
|
Liu C, Tu FX and Chen X: Neuroprotective
effects of apigenin on acute transient focal cerebral
ischemia-reperfusion injury in rats. Zhong Yao Cai. 31:870–873.
2008.(In Chinese).
|
|
2
|
Svehliková V, Bennett RN, Mellon FA, et
al: Isolation, identification and stability of acylated derivatives
of apigenin 7-O-glucoside from chamomile (Chamomilla
recutita [L.] Rauschert). Phytochemistry. 65:2323–2332.
2004.PubMed/NCBI
|
|
3
|
Birt DF, Hendrich S and Wang W: Dietary
agents in cancer prevention: flavonoids and isoflavonoids.
Pharmacol Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manach C, Scalbert A, Morand C, Rémésy C
and Jiménez L: Polyphenols: food sources and bioavailability. Am J
Clin Nutr. 79:727–747. 2004.PubMed/NCBI
|
|
6
|
Yang CS, Landau JM, Huang MT and Newmark
HL: Inhibition of carcinogenesis by dietary polyphenolic compounds.
Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bevilacqua L, Buiarelli F, Coccioli F and
Jasionowska R: Identification of compounds in wine by HPLC-tandem
mass spectrometry. Ann Chim. 94:679–689. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng PW, Chiang LC and Lin CC: Apigenin
induced apoptosis through p53-dependent pathway in human cervical
carcinoma cells. Life Sci. 76:1367–1379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu HF, Chie YJ, Yang MS, et al: Apigenin
induces apoptosis in human lung cancer H460 cells through caspase-
and mitochondria-dependent pathways. Hum Exp Toxicol. 30:1053–1061.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong Y, Krisanapun C, Lee SH, et al:
Molecular targets of apigenin in colorectal cancer cells:
involvement of p21, NAG-1 and p53. Eur J Cancer. 46:3365–3374.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruela-de-Sousa RR, Fuhler GM, Blom N,
Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of
apigenin on leukemia cell lines: implications for prevention and
therapy. Cell Death Dis. 1:e192010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li ZD, Hu XW, Wang YT and Fang J: Apigenin
inhibits proliferation of ovarian cancer A2780 cells through Id1.
FEBS Lett. 583:1999–2003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shukla S, MacLennan GT, Flask CA, et al:
Blockade of beta-catenin signaling by plant flavonoid apigenin
suppresses prostate carcinogenesis in TRAMP mice. Cancer Res.
67:6925–6935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu LZ, Fang J, Zhou Q, Hu X, Shi X and
Jiang BH: Apigenin inhibits expression of vascular endothelial
growth factor and angiogenesis in human lung cancer cells:
implication of chemoprevention of lung cancer. Mol Pharmacol.
68:635–643. 2005.PubMed/NCBI
|
|
15
|
Fang J, Xia C, Cao Z, Zheng JZ, Reed E and
Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via
PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19:342–353. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mirzoeva S, Kim ND, Chiu K, Franzen CA,
Bergan RC and Pelling JC: Inhibition of HIF-1 alpha and VEGF
expression by the chemopreventive bioflavonoid apigenin is
accompanied by Akt inhibition in human prostate carcinoma PC3-M
cells. Mol Carcinog. 47:686–700. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu E, Hjelle B and Bishop JM:
Transforming genes in chronic myelogenous leukemia. Proc Natl Acad
Sci USA. 85:1952–1956. 1988. View Article : Google Scholar
|
|
18
|
O’Bryan JP, Frye RA, Cogswell PC, et al:
axl, a transforming gene isolated from primary human myeloid
leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell
Biol. 11:5016–5031. 1991.PubMed/NCBI
|
|
19
|
Rochlitz C, Lohri A, Bacchi M, et al: Axl
expression is associated with adverse prognosis and with expression
of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results
from a multicenter trial of the Swiss Group for Clinical Cancer
Research (SAKK). Leukemia. 13:1352–1358. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berclaz G, Altermatt HJ, Rohrbach V,
Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of
the receptor tyrosine kinase axl in normal and malignant human
breast. Ann Oncol. 12:819–824. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Craven RJ, Xu LH, Weiner TM, et al:
Receptor tyrosine kinases expressed in metastatic colon cancer. Int
J Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ito T, Ito M, Naito S, et al: Expression
of the Axl receptor tyrosine kinase in human thyroid carcinoma.
Thyroid. 9:563–567. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nemoto T, Ohashi K, Akashi T, Johnson JD
and Hirokawa K: Overexpression of protein tyrosine kinases in human
esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shieh YS, Lai CY, Kao YR, et al:
Expression of axl in lung adenocarcinoma and correlation with tumor
progression. Neoplasia. 7:1058–1064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hutterer M, Knyazev P, Abate A, et al: Axl
and growth arrest-specific gene 6 are frequently overexpressed in
human gliomas and predict poor prognosis in patients with
glioblastoma multiforme. Clin Cancer Res. 14:130–138. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun WS, Fujimoto J and Tamaya T:
Coexpression of growth arrest-specific gene 6 and receptor tyrosine
kinases Axl and Sky in human uterine endometrial cancers. Ann
Oncol. 14:898–906. 2003. View Article : Google Scholar
|
|
27
|
Gustafsson A, Martuszewska D, Johansson M,
et al: Differential expression of Axl and Gas6 in renal cell
carcinoma reflecting tumor advancement and survival. Clin Cancer
Res. 15:4742–4749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Byers LA, Diao L, Wang J, et al: An
epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a
therapeutic target for overcoming EGFR inhibitor resistance. Clin
Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu L, Greger J, Shi H, et al: Novel
mechanism of lapatinib resistance in HER2-positive breast tumor
cells: activation of AXL. Cancer Res. 69:6871–6878. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Holland SJ, Powell MJ, Franci C, et al:
Multiple roles for the receptor tyrosine kinase axl in tumor
formation. Cancer Res. 65:9294–9303. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giles KM, Kalinowski FC, Candy PA, et al:
Axl mediates acquired resistance of head and neck cancer cells to
the epidermal growth factor receptor inhibitor erlotinib. Mol
Cancer Ther. 12:2541–2558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Birt DF, Walker B, Tibbels MG and Bresnick
E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and
indole-3-carbinol. Carcinogenesis. 7:959–963. 1986. View Article : Google Scholar
|
|
33
|
Liang YC, Huang YT, Tsai SH, Lin-Shiau SY,
Chen CF and Lin JK: Suppression of inducible cyclooxygenase and
inducible nitric oxide synthase by apigenin and related flavonoids
in mouse macrophages. Carcinogenesis. 20:1945–1952. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi JS, Choi YJ, Park SH, Kang JS and
Kang YH: Flavones mitigate tumor necrosis factor-alpha-induced
adhesion molecule upregulation in cultured human endothelial cells:
role of nuclear factor-kappa B. J Nutr. 134:1013–1019. 2004.
|
|
35
|
Plaumann B, Fritsche M, Rimpler H,
Brandner G and Hess RD: Flavonoids activate wild-type p53.
Oncogene. 13:1605–1614. 1996.PubMed/NCBI
|
|
36
|
Lepley DM and Pelling JC: Induction of
p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent
apigenin. Mol Carcinog. 19:74–82. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shukla S and Gupta S: Molecular mechanisms
for apigenin-induced cell-cycle arrest and apoptosis of hormone
refractory human prostate carcinoma DU145 cells. Mol Carcinog.
39:114–126. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Y, Ye X, Tan C, et al: Axl as a
potential therapeutic target in cancer: role of Axl in tumor
growth, metastasis and angiogenesis. Oncogene. 28:3442–3455. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ye X, Li Y, Stawicki S, et al: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gusenbauer S, Vlaicu P and Ullrich A: HGF
induces novel EGFR functions involved in resistance formation to
tyrosine kinase inhibitors. Oncogene. 32:3846–3856. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Z, Lee JC, Lin L, et al: Activation
of the AXL kinase causes resistance to EGFR-targeted therapy in
lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Postel-Vinay S and Ashworth A: AXL and
acquired resistance to EGFR inhibitors. Nat Genet. 44:835–836.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dufies M, Jacquel A, Belhacene N, et al:
Mechanisms of AXL overexpression and function in Imatinib-resistant
chronic myeloid leukemia cells. Oncotarget. 2:874–885.
2011.PubMed/NCBI
|
|
44
|
Mahadevan D, Cooke L, Riley C, et al: A
novel tyrosine kinase switch is a mechanism of imatinib resistance
in gastrointestinal stromal tumors. Oncogene. 26:3909–3919. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hong J and Belkhiri A: AXL mediates TRAIL
resistance in esophageal adenocarcinoma. Neoplasia. 15:296–304.
2013.PubMed/NCBI
|
